Cravath’s New York Office Moves to Two Manhattan West
On August 27, 2012, IBM and Kenexa announced that the two companies have entered into a definitive merger agreement for IBM to acquire Kenexa in an all-cash transaction at a price of $46.00 per share, or a net price of approximately $1.3 billion. Cravath represented IBM in connection with this transaction. The acquisition, which is subject to Kenexa shareholder approval, applicable regulatory clearances and other customary closing conditions, is expected to close in the fourth quarter of 2012.
Kenexa is a leading provider of recruiting and talent management solutions. Kenexa brings a unique combination of Cloud-based technology and consulting services that integrates both people and processes, allowing organizations to create a smarter workforce across their most critical business functions.
The Cravath team included associate Deborah R. Eltgroth on M&A matters; partner Michael L. Schler, practice area attorney Michael Krasnovsky and associates Jonathan J. Katz and Michelle M. Garrett on executive compensation and benefits matters; partner Andrew W. Needham and associates J. Leonard Teti II, Neetin Gulati and Andrew Carlon on tax matters; and partner Matthew Morreale on environmental matters. Summer associate Daniel Cerqueira also worked on corporate matters.
Deals & Cases
October 04, 2024
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
September 10, 2024
On September 9, 2024, IBM announced its intent to acquire Accelalpha, a global Oracle services provider with deep expertise helping clients digitize core business operations and accelerate adoption of Oracle Cloud Applications. This acquisition expands IBM's Oracle consulting expertise in supply chain and logistics, finance, enterprise performance management and customer transformation. Cravath is representing IBM in connection with the transaction.
Deals & Cases
September 05, 2024
On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.